PARIS--(BUSINESS WIRE)--DBV Technologies (DBV), a biotechnology company specializing in innovative products for the diagnosis and the treatment of food allergies, announced today that its lead product VIASKIN® PEANUT for Peanut Specific EPicutaneous ImmunoTherapy (EPIT) has been selected to be evaluated in a Phase II study led by the U.S. Consortium of Food Allergy Research (CoFAR).
